Randomized Trial of Adult Subjects With Generalized Anxiety Disorder

Inclusion Criteria:

- Primary diagnosis of generalized anxiety disorder (GAD) either moderate or severe as
per Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) as
confirmed by the MINI at Screening, in addition to a psychiatric evaluation by a
board- certified or Biohaven-approved board-eligible psychiatrist; The duration of
illness must be ≥ 1 year

- HAM-A Total Score of ≥ 18 at both Screening and Baseline

- CGI-S score of ≥ 4 at both Screening and Baseline

- Determined by the investigator to be medically stable at baseline/randomization as
assessed by medical history, physical examination, laboratory test results, and
electrocardiogram testing. Subjects must be physically able and expected to complete
the trial as designed

- Minimum of 6 years of education or equivalent to complete necessary scales and
understand consent forms

- Subjects must be able to understand and agree to comply with the prescribed dosage
regimens and procedures; report for regularly scheduled office visits; and reliably
communicate with study personnel about adverse events and concomitant medications

- Women of childbearing potential must have a negative serum pregnancy test at screening
and a negative urine pregnancy test prior to dosing at Baseline

Exclusion Criteria:

- Subjects with a primary DSM-V psychiatric disorder diagnosis other than GAD within the
past 6-months. Note: Subjects with a secondary diagnosis of comorbid social anxiety
disorder or specific phobia are allowed, if in the investigator's judgement, the
diagnosis is not sufficiently prominent and active so as to be confound the assessment
of GAD symptoms

- Subjects should be excluded at screening or baseline if any medical or psychiatric
condition other than GAD, as specified in the inclusion criteria, could predominantly
explain or contribute significantly to the subjects' symptoms or that could confound
assessment of GAD symptoms

- Patients who report a history of inadequate response (per investigator judgement) to
three (3) or more adequate trials (including current trial) of any SSRI or SNRI, at an
adequate dose and adequate duration (at least 8 weeks) for the treatment of GAD within
the 3 years prior to randomization

- HAM-D-17 item 1 of >1 at Screening or Baseline

- HAM-D-17 of > 19 at Baseline

- Any eating disorder within the last 12 months prior to Screening

- Acute suicidality in the last 12 months, or suicide attempt or self-injurious behavior
in the last 12 months prior to Screening

- Score of >0 on the Sheehan Suicidality Tracking Scale for the period of 12 months
prior to screening, and at baseline

- History of psychosurgery, deep brain stimulation (DBS) or electroconvulsive therapy
(ECT)